1. Introduction {#s0005}
===============

Obesity has complex effects on bone mass and skeletal fragility. High body mass increases bone mineral density (BMD, g/cm^2^) via greater mechanical loading, and soft tissue padding dampens impact forces during falls ([@bb0150]; [@bb0070]), such that body mass index (BMI) is correlated positively with BMD ([@bb0330]; [@bb0280]; [@bb0395]; [@bb0020]) and negatively with fragility fractures of the hip ([@bb0100]). However, recent studies have challenged the notion that high body mass is unequivocally beneficial to bone. First, the skeleton adapts most closely to lean body mass, such that individuals with low lean mass and high percent body fat may have lower BMD than expected for their total body mass ([@bb0180]; [@bb0015]; [@bb0470]; [@bb0340]; [@bb0030]). Second, obese men and women are at elevated risk for humerus and ankle fractures, suggesting lower resistance to fracture ([@bb0335]; [@bb0090]; [@bb0380]; [@bb0385]). Finally, obesity-induced inflammation increases adipocytokine levels and decreases BMD in humans ([@bb0015]).

Potential detrimental effects of fat mass on bone health are of particular concern in adolescents who are obese during the time of peak bone mass acquisition ([@bb0025]; [@bb0040]). Obese children have higher fracture risk and lower bone mass than expected for their height and weight ([@bb0175]; [@bb0140]; [@bb0475]; [@bb0355]), suggesting a failure of skeletal adaptation to total body mass ([@bb0125]; [@bb0375]; [@bb0365]; [@bb0225]), and obesity-induced chronic inflammation is associated with lower adolescent BMD ([@bb0405]; [@bb0290]). Understanding the mechanisms by which high fat mass impairs skeletal acquisition is of critical importance because low young adult bone mass is a risk factor for skeletal fragility later in life ([@bb0415]; [@bb0235]). By one estimate, a 10% increase in peak bone mass may decrease adult fracture risk by up to 50% ([@bb0045]). Conversely, failure to reach peak bone mass likely increases the incidence of later osteoporosis and fracture ([@bb0285]).

Understanding the interrelationships between obesity and bone mass is challenging because several of the factors contributing to obesity, including diet, heredity, activity level, socioeconomic status, and metabolic disease, can also directly affect bone. The goal of this study is to delineate the impact of high fat intake vs. the impact of diet-induced obesity (DIO) due to a high calorie diet on skeletal acquisition. Although obesity results from overconsumption, and is often linked to high carbohydrate diets, Americans also tend to have a high fat intake ([@bb0325]), which is associated with lower BMD and higher fracture risk compared to unsaturated fats ([@bb0275]). Previous studies using rodent models to test the effects of DIO on bone have focused on high saturated fat (HF) diets, and report such diets increase ([@bb0270]; [@bb0300]), decrease ([@bb0155]; [@bb0160]; [@bb0425]; [@bb0085]; [@bb0055]), or do not change ([@bb0130]; [@bb0005]) bone mass ign wildtype mice, likely due to differences in experimental design. Fewer experimental studies have used diets high in polyunsaturated fats, although HF corn oil diets rich in omega 6 fatty acids decrease bone mass in mice ([@bb0195]) and rats ([@bb0490]), whereas omega 3 fatty acids are beneficial to bone mass in rodent models ([@bb0050]; [@bb0295]).

Here we sought to test whether it is the type of calories (primarily saturated fat vs. primarily carbohydrate) or the number of calories (with chronic overconsumption leading to obesity) that causes bone loss. The overall hypothesis is that both high fat diet itself and the resulting metabolic dysfunction, including obesity, inflammation and impaired glucose tolerance, independently decrease skeletal acquisition. To test this hypothesis, we compared the effect of high saturated fat (HF) diet on bone mass and microarchitecture during rapid skeletal growth in two inbred mouse strains: FVB/J, which do not overeat on HF diet and thus are resistant to DIO, and C57BL/6J (B6), which overeat on HF diet and are DIO-susceptible ([@bb0230]; [@bb0265]). The prediction is that the combination of high saturated fat diet, obesity, and metabolic dysfunction in B6 mice will be more deleterious to skeletal acquisition compared to high saturated fat diet in DIO-resistant FVB mice.

2. Materials and methods {#s0010}
========================

2.1. Dietary intervention {#s0015}
-------------------------

We obtained 3-wk-old female FVB/NJ (FVB) and C57BL/6J (B6) mice (The Jackson Laboratory, Bar Harbor, ME) and randomized them to normal (N) or high fat (HF) diet. N diet mice were fed a purified, phytoestrogen-free diet ad libitum (Research Diets 12450B, 10% kcal/fat (4% lard +6% soybean oil), 20% protein, 70% carbohydrate). HF mice were fed a high-fat purified, phytoestrogen-free diet ad libitum (Research Diets 12451, 45% kcal/fat (39% lard +6% soybean oil), 20% protein, 35% carbohydrate). The HF diet was 50% lower in carbohydrate vs. the N diet (7% vs. 31% corn starch, 17% vs. 35% sucrose, 10% vs. 3% maltodextrin). Fiber and micronutrient content of the experimental diets were identical. Mouse body mass and food intake were measured three times per week on a digital scale. Mice were sacrificed by CO~2~ inhalation at 6, 12 or 20 wks of age (N = 10/group for each strain, diet, and age).

2.2. Glucose tolerance {#s0020}
----------------------

Glucose tolerance tests (GTT) were performed at 12 wks of age using a OneTouch Ultra blood glucose monitor (LifeScan, Inc., Milpitas, CA). Briefly, after an overnight fast, a baseline blood glucose measurement was made via tail nick, mice were injected IP with sterile glucose solution (1 g/kg), and blood glucose was measured at 15, 30, 60, and 120 min following injection ([@bb0215]).

2.3. Bone mineral density and body composition {#s0025}
----------------------------------------------

Longitudinal in vivo assessment of whole body (exclusive of the head) bone mineral density (WBBMD, g/cm^2^), bone mineral content per body mass (WBBMC/BM, g/g) and body composition (percent body fat) was performed at 3, 6, 9, 12, and 20 wks of age using peripheral dual-energy x-ray absorptiometry (pDXA, PIXImusII, GE Lunar Corp.), as previously described ([@bb0075]; [@bb0065]; [@bb0145]).

2.4. Specimen harvesting/preparation {#s0030}
------------------------------------

Gonadal white adipose depots were excised and weighed. Femurs and lumbar vertebrae were harvested and cleaned of soft tissue. The right femur and L5 vertebral body were prepared for imaging and biomechanical testing by wrapping in saline-soaked gauze and freezing at −20 °C as previously described ([@bb0110]). The left femur was prepared for histology in 70% ethanol at 4 °C until processing.

2.5. Trabecular and cortical bone morphology by μCT {#s0035}
---------------------------------------------------

Bone morphology and microarchitecture were assessed with high-resolution microcomputed tomography (μCT40, Scanco Medical, Brüttisellen, Switzerland), as previously described ([@bb0185]). In brief, the distal femoral metaphysis and L5 vertebral body were scanned using a 12 μm^3^ isotropic voxel size, 70 kVP, 114 mA, and 200 ms integration time, and were subjected to Gaussian filtration and segmentation. At the distal femur, evaluation of transverse CT slices began at 360 μm proximal to the distal growth plate and continued 1800 μm proximally. Images were thresholded using an adaptive-iterative algorithm.([@bb0400]; [@bb0315]; [@bb0390]) The average adaptive-iterative threshold of all specimens from each strain was applied as a fixed threshold to segment bone from soft tissue (FVB: 296 mg hydroxyapatite (HA)/cm^3^, B6: 256 mg HA/cm^3^). At the femoral mid-diaphysis, transverse μCT slices spanning 600 μm were obtained to assess cortical bone parameters and segmented using a fixed threshold of 670 mg HA/cm^3^. In the fifth lumbar vertebra, transverse CT slices were evaluated throughout the body of each vertebra (2400--3000 μm), excluding the superior and inferior growth plates. As in the distal femur, the average adaptive-iterative threshold of all specimens from each strain was used as a fixed threshold to segment bone from soft tissue (FVB: 296 mg hydroxyapatite (HA)/cm^3^, B6: 318 mg HA/cm^3^). In the trabecular bone region we assessed bone volume fraction (BV/TV, %), trabecular thickness (Tb.Th, μm), trabecular separation (Tb.Sp, μm), trabecular number (Tb.N, 1/mm), connectivity density (ConnD 1/mm^3^), and structure model index (SMI). At the femoral midshaft we measured total cross-sectional area, cortical bone area, and medullary area (TA, BA and MA, mm^2^); bone area fraction (BA/TA, %), cortical thickness (μm), antero-posterior and medio-lateral diameters; and area moments of inertia. Procedures followed the 2010 recommendations of the American Society for Bone and Mineral Research ([@bb0080]).

2.6. Bone strength testing {#s0040}
--------------------------

Following μCT scanning, the strength of the femoral midshaft was assessed by 3-point bending (by applying a flexion moment in the anterior-posterior plane) using previously described methods (35,40--42). Briefly, specimens were thawed to room temperature in a calcium-buffered saline bath, to ensure adequate hydration. A low force mechanical testing system (Bose Electroforce 3230, with 100 N load cell) was used to apply constant displacement at a rate of 0.03 mm/s. The distance between load supports was 8.0 mm. Force-displacement data were used to determine structural properties (ultimate moment (N\*mm), bending stiffness (N\*mm/mm) and post-yield displacement (mm)), and then data for each specimen were adjusted for the appropriate femoral midshaft area moment of inertia, as measured on the μCT scans, to derive estimated elastic modulus (GPa).

2.7. Serum hormones {#s0045}
-------------------

Blood was collected at sacrifice by cardiac puncture and ELISA was used to measure serum leptin, as previously described ([@bb0110]; [@bb0115]).

2.8. Marrow adiposity {#s0050}
---------------------

Marrow adiposity was quantified using static histomorphometry as previously described ([@bb0110]). Terminology and units followed the recommendations of the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research ([@bb0105]).

2.9. Statistical analyses {#s0055}
-------------------------

The effects of diet, strain and age on bone variables were evaluated using a full factorial General Linear Model (GLM) in SPSS (IBM, Armonk, NY). If the overall model indicated a significant effect of diet, diet\*age, diet\*strain, or diet\*age\*strain, we then stratified the GLM by age and strain to obtain p values for diet (HF vs. N) specific to a given strain at a given age. Only such significant pairwise differences are reported in the results (alpha = 0.05). To adjust for body mass differences, we regressed the variable of interest (i.e., bone cross-sectional properties) vs. body mass and compared residuals ([@bb0110]).

3. Results {#s0060}
==========

3.1. Body size and composition, whole-body BMD, and hormone levels {#s0065}
------------------------------------------------------------------

HF diet had strain-dependent effects on food intake, body mass, body composition, leptin levels, and bone density. In DIO-resistant FVB mice, caloric intake (kCal/day) did not differ between N and HF diets, and food consumption remained stable over time ([Fig. 1](#f0005){ref-type="fig"}A). There were no differences between FVB N and HF in body mass, body fat (%) by DXA, femur length, gonadal white adipose tissue mass, or serum leptin ([Fig. 1](#f0005){ref-type="fig"}B--D, [Table 1](#t0005){ref-type="table"}). FVB HF mice had modestly impaired glucose tolerance at 0--15 min by GTT (p \< 0.05, [Fig. 1](#f0005){ref-type="fig"}E). Longitudinal in vivo DXA showed no differences in WBBMD or in whole body bone mineral content per body mass (WBBMC/BM) in FVB HF vs. N ([Fig. 1](#f0005){ref-type="fig"}F).Fig. 1A. Food intake (kCal/day), B. Body mass (g), C. Body fat (%) via Piximus, D. Leptin (ng/ml), E. Glucose tolerance at 12 wks of age (mg/dl), F. Whole body bone mineral density (WBBMD, g/cm^2^). Significant differences as shown (\*p \< 0.05).Fig. 1Table 1Body size and body composition in female FVB/J and C57BL/6J mice fed a normal (N) or high fat (HF) diet from 3 wks of age to 6, 12, or 20 wks of age (mean ± SD).Table 1B6FVBP~diet~P~strain⁎\ diet~P~strain⁎diet⁎age~6 wks12 wks20 wks6 wks12 wks20 wksNHFNHFNHFNHFNHFNHFMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDFemur length (mm)13.880.6414.210.2615.010.21**15.29**0.2215.770.2615.910.1713.280.3413.590.3514.590.2214.620.1815.060.2415.010.230.002NSNSWBBMC/BM (g/g \* 100)1.580.191.620.121.860.12**1.64**0.162.100.07**1.61**0.161.550.121.520.111.880.191.840.221.940.121.780.12≤0.002NSNSGonadal WAT (g)0.280.080.270.100.340.09**0.79**0.290.270.04**1.30**0.450.470.16N/AN/A0.580.170.660.200.770.300.960.35\<0.001\<0.0010.028[^1]

In contrast, DIO-prone B6 mice exhibited hyperphagia on HF diet from 16 to 20 wks of age, consuming 40--93% more calories vs. N (p \< 0.05 for both, [Fig. 1](#f0005){ref-type="fig"}A). B6 mice on HF diet were heavier, had higher percent body fat by DXA and higher gonadal white adipose tissue mass, and had longer femurs vs. mice on N diet (p \< 0.05 for all, [Fig. 1](#f0005){ref-type="fig"}B--C, [Table 1](#t0005){ref-type="table"}). B6 HF mice also had 74% higher leptin levels vs. B6 N at 12 wks of age (p = 0.012, [Fig. 1](#f0005){ref-type="fig"}D). Glucose tolerance was substantially impaired in B6 HF vs. N from 30 to 90 min (p \< 0.05, [Fig. 2](#f0010){ref-type="fig"}E). WBBMD was higher in B6 HF vs. N mice from 6 to 12 wks of age (p \< 0.05, [Fig. 1](#f0005){ref-type="fig"}F), whereas WBBMC/BM was lower from 9 to 20 wks of age in B6 HF vs. N (p \< 0.05, [Table 1](#t0005){ref-type="table"}).Fig. 2A. Distal femur BV/TV (%), B. Distal femur connectivity density (/mm), C. Midshaft femur BA/TA (%), D. Midshaft femur pMOI (mm^4^), E. Lumbar vertebra Tb.N (/mm), F. Lumbar vertebra connectivity density (/mm). Significant differences (p \< 0.05) as shown for unadjusted data (\*); following body mass adjustment, pMOI was lower in B6 HF vs. N mice (^\#^).Fig. 2

3.2. Bone morphology: Trabecular bone at distal femur and cortical bone at midshaft femur {#s0070}
-----------------------------------------------------------------------------------------

In DIO-resistant FVB, HF diet was associated with early deficits in trabecular bone at the distal femur that attenuated at later ages. FVB HF had worse trabecular architecture than N mice at 6 weeks of age (p \< 0.05 for all, [Figs. 2](#f0010){ref-type="fig"}A--B and [Table 2](#t0010){ref-type="table"}), but not at 12 and 20 wks of age. In contrast, in B6 mice, HF diet was associated with consistent decrements in trabecular bone at 12 and 20 wks of age, with significantly lower Tb.BV/TV (−21%), Tb.N (−14%), and Conn.D (−40%) and higher Tb.Sp (17%) and SMI (+10%) at 12 weeks of age, and lower Tb.N (−6%) and Conn.D (−23%) and higher Tb.Sp (+7%) at 20 weeks of age (p ≤ 0.04 for all, [Fig. 2](#f0010){ref-type="fig"}A--B and [Table 2](#t0010){ref-type="table"}).Table 2Trabecular & cortical bone properties in female FVB/NJ and C57BL/6J mice fed a normal (N) or high fat (HF) diet from 3 wks of age to 6, 12, or 20 wks of age (mean ± SD).Table 2B6FVBP~diet~P~strain⁎diet~P~strain⁎diet⁎age~6 wks12 wks20 wks6 wks12 wks20 wksNHFNHFNHFNHFNHFNHFMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDDistal femur (trabecular)Tb.N (/mm)4.460.234.390.234.150.26**3.59**0.173.470.16**3.28**0.215.650.29**5.09**0.314.010.214.170.373.200.373.130.23\<0.001NS\<0.001Tb.Th (mm)0.0500.0020.0500.0010.0540.0020.0560.0020.0550.0030.0580.0040.0560.002**0.052**0.0020.0560.0020.0550.0010.0590.0020.0580.002NS\<0.001NSTb.Sp (mm)0.2230.0140.2260.0140.2380.016**0.277**0.0130.2830.015**0.302**0.0210.1750.012**0.195**0.0150.2490.0150.2410.0250.3180.0440.3240.0290.0010.070.005SMI2.630.212.770.142.850.18**3.12**0.182.860.222.990.191.720.19**2.31**0.292.320.282.310.232.600.232.520.11\<0.001NS\<0.001  Midshaft femur (cortical)BA (mm^2^)0.560.050.590.030.720.03**0.78**0.040.830.040.84^\#^0.040.640.050.640.030.750.050.720.030.780.060.750.04NS0.001NSTA (mm^2^)1.730.091.780.101.730.091.790.071.780.08**1.87**0.081.600.081.620.071.660.08**1.57**0.091.660.071.620.07NS0.001NSCort.Th (mm)0.1290.0100.1330.0080.1680.0060.1790.0050.1930.0070.189^\#^0.0070.1570.0090.1570.0060.1830.0090.1850.0070.1950.0130.1880.007NS0.053NSI~max~ (mm^4^)0.1760.020**0.195**0.0190.2220.019**0.249**0.0250.2590.0330.281^\#^0.0300.1620.0200.1650.0120.1950.027**0.170**0.0150.1930.0180.1870.017NS\<0.001NSI~min~ (mm^4^)0.0950.0120.1000.0130.1100.011**0.120**0.0070.1250.009**0.133**^\#^0.0090.0950.0110.0970.0090.1120.0110.1040.0110.1200.014**0.109**0.010NS0.001NS  Fifth lumbar vertebra (trabecular)BV/TV (%)26.32.124.84.429.22.429.91.733.72.731.42.923.63.025.73.327.31.826.52.726.53.725.04.8NSNSNSTb.Th (mm)0.0480.0020.0500.0030.0560.002**0.062**0.0020.0660.0030.0670.0040.0520.0030.0530.0040.0630.0040.0600.0020.0660.0040.0620.005NS0.0030.062Tb.Sp (mm)0.1670.011**0.179**0.0140.1870.010**0.199**0.0100.2060.0150.2180.0160.2110.0110.2120.0100.2450.0150.2410.0200.2690.0160.2600.020NS0.003NSSMI0.780.200.960.430.440.220.400.17−0.100.22**0.11**0.261.140.38**0.63**0.370.410.180.570.270.490.320.640.42NS0.100.004[^2]

HF diet decreased femoral cortical bone acquisition in both strains. In particular, while there were no differences at 6 wks of age, by 12 wks of age FVB HF mice had lower cortical cross-sectional properties, including TA (−5%), Imax (−13%), and pMOI (−11%), and at 20 wks of age FVB HF had lower Imin (−9%) (p \< 0.05 for all, [Fig. 2](#f0010){ref-type="fig"}C--D and [Table 2](#t0010){ref-type="table"}). These differences were no longer statistically significant after body mass adjustment. In B6, HF diet appeared to improve cortical bone geometry, but this effect disappeared after adjustment for body mass. Specifically, prior to body mass adjustment, at 6 wks of age B6 HF mice had higher Imax (+11%); at 12 wks of age B6 HF had higher BA (+8%), Imax (+12%), Imin (+9%), and pMOI (+11%); and at 20 wks of age B6 HF had higher TA (+5%) and Imin (+6%) (p \< 0.05 for all, [Fig. 2](#f0010){ref-type="fig"}C--D and [Table 2](#t0010){ref-type="table"}). After body mass adjustment, there were no significant effects of HF diet on cortical bone geometry until 20 weeks of age, at which time B6 HF had significantly lower BA, Cort.Th, Imax, Imin, and pMOI vs. N (p \< 0.05 for all, indicated by ^\#^ in [Fig. 2](#f0010){ref-type="fig"}D and [Table 2](#t0010){ref-type="table"}).

3.3. Bone morphology: Trabecular bone at lumbar vertebrae {#s0075}
---------------------------------------------------------

As with the femur, the fifth lumbar vertebra exhibited strain-dependent effects of HF diet. In DIO-resistant FVB, vertebral trabecular bone properties were similar in HF vs. N mice at 6, 12, and 20 wks of age, although SMI was lower in FVB HF vs. N at 6 wks of age (−45%, p = 0.009, [Fig. 2](#f0010){ref-type="fig"}E--F and [Table 2](#t0010){ref-type="table"}). However, in DIO-prone B6, HF mice had 5--6% lower Tb.N at 6 and 12 wks of age and 16--21% lower Conn.D at all ages, with 10% higher Tb.Th at 12 wks and 2-fold higher (i.e. worse) SMI at 20 wks of age vs. N mice (p \< 0.05 for all, [Fig. 2](#f0010){ref-type="fig"}E--F and [Table 2](#t0010){ref-type="table"}).

3.4. Distal femur bone marrow adiposity {#s0080}
---------------------------------------

At 12 wks of age, B6 HF mice had a twofold higher adipocyte volume per total volume (Ad.V/TV, %) vs. B6 N (p = 0.006), but there was no effect of HF diet on marrow adiposity in FVB mice ([Table 3](#t0015){ref-type="table"}).Table 3Distal femur bone marrow adiposity in female FVB/NJ and C57BL/6J mice fed a normal (N) or high fat (HF) diet from 3 wks of age to 12 wks of age (mean ± SD).Table 3B6FVBP~diet~P~strain⁎diet~NHFNHFMeanSDMeanSDMeanSDMeanSDAd.V/TV (%)2.141.52**4.52**2.350.110.080.030.020.0570.044[^3]

3.5. Bone strength {#s0085}
------------------

Mechanical testing showed that femora from B6 HF mice had higher stiffness (N) at 12 weeks of age (p \< 0.05, [Table 4](#t0020){ref-type="table"}). In contrast, femora from FVB HF had higher stiffness at 6 wks of age, but lower stiffness and maximum force vs. N at 20 wks of age (p \< 0.05 for all, [Table 4](#t0020){ref-type="table"}). There were no effects of HF diet on the apparent elastic modulus or postyield displacement in femora from either strain.Table 4Midshaft femoral cortical bone mechanical properties in female FVB/J and C57BL/6J mice fed a normal (N) or high fat (HF) diet from 3 wks of age to 6, 12, or 20 wks of age (mean ± SD).Table 4B6FVBP~diet~P~strain⁎diet~P~strain⁎diet⁎age~6 wks12 wks20 wks6 wks12 wks20 wksNHFNHFNHFNHFNHFNHFMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDMeanSDStiffness (N/mm)42.49.041.29.161.29.4**71.6**4.977.110.582.79.852.37.0**61.2**8.776.611.178.67.997.18.9**85.5**12.1NS0.0730.004Maximum Force (N)10.61.310.41.514.51.115.41.117.61.117.61.912.01.112.91.517.40.917.11.319.91.8**17.9**1.7NSNS0.040Estimated Young\'s modulus (GPa)3.822.343.542.005.831.536.431.176.491.086.381.264.772.435.252.677.721.998.551.269.130.979.001.64NSNSNSPostyield Displacement (mm)1.410.321.190.661.240.571.310.540.690.320.800.160.540.180.560.320.390.110.420.150.300.070.330.12NSNSNS[^4]

4. Discussion {#s0090}
=============

In this study, we tested the effects of high fat (HF) diet on metabolism and skeletal acquisition in young, rapidly growing female mice from two strains: FVB, which resists diet-induced obesity, and B6, which readily develops diet-induced obesity ([@bb0230]). We hypothesized that the combination of high saturated fat diet, obesity, and metabolic dysfunction in B6 mice would be more deleterious to skeletal acquisition compared to high saturated fat diet alone in DIO-resistant FVB mice.

In keeping with previous studies, we found that high fat diet induced a metabolic phenotype including obesity and glucose intolerance, higher leptin, and higher marrow adiposity in B6 mice, while FVB were largely unaffected ([@bb0270]; [@bb0300]; [@bb0155]; [@bb0160]; [@bb0425]; [@bb0085]; [@bb0055]; [@bb0130]; [@bb0005]; [@bb0230]; [@bb0265]). We also observed strain-specific effects of HF diet on the skeleton: B6 on high fat diet had higher bone mineral density from 6 to 12 wks of age, but lower bone mineral content for their body mass from 9 to 20 wks of age, indicating bone mineral deposition did not keep pace with their weight gain. In contrast, FVB mice on a high fat diet had no changes in bone mineral density or content. B6 mice on a high fat diet had worse trabecular architecture at 12 and 20 wks of age, whereas FVB mice on high fat diet had worse trabecular bone architecture at 6 wks of age but not thereafter, perhaps because bone loss was slower in HF vs. N mice after 6 wks of age. B6 HF mice had lower body mass-adjusted cortical bone properties vs. normal diet controls at 12 and 20 wks of age, but FVB HF mice did not, although at 20 wks of age FVB HF had lower femoral bone strength vs. N. These data provide partial support for our hypothesis that most of the effects of high fat diet on the skeleton are mediated via diet-induced obesity and metabolic dysfunction, particularly in trabecular bone. However, these effects were complex and appeared to attenuate with age, such that by 20 wks of age, there were few significant skeletal differences between HF and N mice of either strain.

4.1. Comparison to prior studies of high fat diet and bone mass {#s0095}
---------------------------------------------------------------

Previous studies of the influence of high fat diet on bone in mice found a range of effects from positive to negative. Two studies of male C57BL/6J mice from 12 to 23 or 7 to 28 wks of age found HF diet was associated with higher femoral trabecular thickness and trabecular bone mineral content, as well as higher cortical bone area, total area, cortical thickness, and polar moment of inertia (unadjusted for body mass), despite lower bone formation and high marrow adiposity ([@bb0270]; [@bb0300]). In contrast, other studies reported HF diet from 3 wks or 8 wks to 14 to 17 wks of age had little effect on femoral trabecular or cortical bone in wildtype mice, although marrow adiposity increased ([@bb0130]; [@bb0005]; [@bb0445]), and osteocalcin decreased while TRACP5b increased ([@bb0490]). Finally, several studies of HF diet in male and female B6 beginning at 4 to 7 wks and ending at 14 to 31 wks of age found deleterious effects in the distal femur and proximal tibia including lower trabecular BV/TV, increased bone turnover, and higher RANKL, TNF, and PPAR-gamma along with higher marrow adiposity and lower fracture resistance ([@bb0155]; [@bb0160]; [@bb0425]; [@bb0085]; [@bb0410]; [@bb0350]). It is challenging to integrate these disparate findings, although it should be noted that the studies reporting positive effects of HF diet on bone mass tended to be initiated in mice that were older (i.e. 7 to 12 wks of age) than those studies reporting neutral or negative effects (i.e. initiated at 3 to 8 wks of age). This difference is critical because skeletal acquisition in B6 mice peaks between 3 and 6 wks of age ([@bb0185]), such that bone may be particularly susceptible to metabolic insult during this interval. Our data in female B6 from 3 to 20 wks of age concur with the finding that HF is deleterious to bone mass during rapid skeletal acquisition. In terms of marrow adiposity, the association of HF diet with higher BMAT is remarkably consistent across studies, regardless of whether bone mass is higher, lower, or unchanged ([@bb0270]; [@bb0155]; [@bb0160]; [@bb0425]; [@bb0130]; [@bb0005]; [@bb0445]; [@bb0410]). Thus our finding of higher BMAT in B6 HF at 12 wks of age is likely representative of marrow adiposity at other ages as well. To the best of our knowledge, this is the first study to test the effects of HF diet on bone mass in FVB mice, so our data cannot be compared to prior work in this strain. The mechanisms underlying the age-related effects of HF diet on distal femur trabecular architecture in this strain are unclear and should be tested in future studies. One possibility is that genetic differences between strains mediate the effects of HF diet on the skeleton. For example, several recent studies have demonstrated significant strain-related differences in the skeletal response to saturated fats and unsaturated omega 3 vs. omega 6 fats involving nutrition-by-gene interactions with peroxisome proliferator-activated receptor-gamma (PPARγ) ([@bb0005]; [@bb0050]).

4.2. Mechanisms for deleterious effects of obesity on bone mass {#s0100}
---------------------------------------------------------------

Several potential mechanisms link obesity and metabolic dysregulation to bone metabolism, including chronic inflammation, hyperleptinemia, and hyperglycemia. Cytokine production in adipose tissue induces chronic inflammation that has been implicated in atherosclerosis and insulin resistance ([@bb0420]; [@bb0480]), as well as bone loss ([@bb0345]) and lower bone mineral density in adolescents ([@bb0405]; [@bb0290]). Inflammatory markers including tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and interleukin-6 (IL-6) can stimulate osteoclast activity via increased proliferation of preosteoclastic cells and upregulated RANKL expression ([@bb0245]). A recent comparison of B6 and FVB metabolism following 8 wks of HF diet also found that although B6 mice had smaller adipocytes, they exhibited higher levels of proinflammatory cytokines and macrophages, along with higher tissue hypoxia and expression of angiogenic genes compared to FVB ([@bb0250]). The authors concluded that B6 mice have a greater capacity to expand their adipose depots in response to high fat diet compared to FVB, contributing to their DIO but also potentially contributing to inflammation-induced metabolic dysregulation and bone loss ([@bb0250]). It is also possible that these metabolic differences simply reflect the fact that B6 overeat on HF diet whereas FVB do not. Recently, Bornstein et al. tested the effect of metformin in C57BL/6J mice after HF diet, and found that DIO was not deleterious to trabecular bone architecture but led to decreased midshaft cortical bone area fraction and higher marrow adiposity in the femur and tibia ([@bb0055]). Metformin treatment did not affect body mass or percent body fat, but partially reversed the skeletal phenotype, normalized blood glucose, increased osteoblast number, and caused alterations in serum metabolites and in the gut microbiome ([@bb0340]). These data support the hypothesis that metabolic dysfunction significantly contributes to the skeletal phenotype in DIO.

The adipokine leptin also modulates both cortical and trabecular bone mass, both directly via osteoblast leptin receptors and indirectly via neural pathways ([@bb0465]). Direct effects of leptin in peripheral tissues are generally osteogenic, including stimulation of periosteal bone apposition and promoting differentiation of mesenchymal stem cells (MSCs) to osteoblasts rather than adipocytes ([@bb0095]; [@bb0455]; [@bb0210]). In addition, reports indicate that leptin can reduce bone loss following ovariectomy or hindlimb unloading ([@bb0210]; [@bb0305]; [@bb0165]). Thus we might expect that high circulating leptin due to DIO would maintain or increase bone mass in B6 mice ([@bb0095]; [@bb0455]; [@bb0135]; [@bb0450]). However, in this study DIO-induced hyperleptinemia in B6 mice at 12 wks of age was associated with lower cortical and trabecular bone mass. At 20 wks of age, B6 HF were not hyperleptinemic, despite high body mass and percent body fat, and their trabecular and cortical bone mass did not differ from B6 N. The decrease in leptin in B6 HF from 12 to 20 wks of age was unexpected given the high adiposity of these mice. One potential mechanism involves a high fat diet-induced increase in peroxisome proliferator-activated receptor gamma,

In terms of the skeletal phenotype, these findings are consistent with prior studies demonstrating the osteogenic effects of leptin in humans ([@bb0485]; [@bb0430]) and in animal models ([@bb0170]; [@bb0240]; [@bb0360]; [@bb0460]) are most pronounced in hypoleptinemic individuals. Hyperleptinemia may induce leptin resistance ([@bb0205]) and upregulate deleterious inflammatory pathways in bone ([@bb0500]), an intriguing possibility that deserves further study.

Finally, HF diet also induced impaired glucose tolerance, particularly in B6 mice. Although few studies in animal models have isolated the effects of impaired glucose tolerance on bone mass, in humans there is a link between impaired glucose tolerance and lower bone mineral content in adolescents ([@bb0370]; [@bb0010]). More broadly, hyperglycemia is known to impair osteoblast function in vitro, and has been implicated in diabetes-induced osteoporosis and skeletal fragility ([@bb0310]; [@bb0060]; [@bb0200]; [@bb0120]). These data suggest that treating the metabolic consequences of obesity, such as inflammation and impaired glucose tolerance, might help maximize peak bone mass and reduce future osteoporosis risk in adolescents.

4.3. Limitations and future directions {#s0105}
--------------------------------------

The strengths of our approach include a focus on young, rapidly growing animals, the use of high fat diet to physiologically induce metabolic dysregulation, and the use of inbred mouse strains with contrasting responses to diet induced obesity. However, a limitation of this approach is the possibility that genetic differences between FVB and B6, for example in quantitative trait loci for feeding behavior ([@bb0440]; [@bb0260]) or for metabolic response to macronutrient intake ([@bb0005]), mediate strain-specific responses to HF diet. It is particularly interesting that in FVB mice, HF diet caused worse trabecular bone architecture at 6 wks of age but not thereafter. Further study of resistance vs. susceptibility to overeating across inbred mouse strains may be relevant for understanding why some humans do not gain weight even in an obesogenic environment ([@bb0320]; [@bb0035]). Future studies should further investigate the unexpected apparent decrease in leptin in B6 HF females from 12 wks to 20 wks of age, and should include leptin sensitivity tests to assess the impact of leptin resistance on feeding behavior and body composition ([@bb0255]). An additional limitation is that we currently include only female mice, and there may be sex differences in the response to high fat diet. In addition, our physiological approach to diet-induced obesity induced multiple metabolic changes including hyperleptinemia, high fat mass, and impaired glucose tolerance, thus making it challenging to determine the contributions of each factor to the changes in skeletal acquisition we observed. Finally, there is evidence that the gut microbiome varies across inbred mouse strains ([@bb0220]) and can increase or decrease bone strength ([@bb0190]; [@bb0495]; [@bb0435]). Future studies will include males and will test the effects of treatments including diet and exercise and anti-inflammatory agents on both metabolic dysregulation and skeletal acquisition in high fat diet-induced obesity within a given mouse strain. Future work should also continue to test the role of the gut microbiome in mediating the effects of HF diet on the skeleton ([@bb0055]), particularly the strain-related differences observed in this study.

5. Conclusions {#s0110}
==============

In this study, we sought to test whether the effects of high fat diet on skeletal acquisition differ in the presence or absence of excessive caloric intake leading to obesity and metabolic disease. We did this by comparing the effects of high fat diet on metabolism and skeletal acquisition in FVB mice, which resist diet-induced obesity, and B6 mice, which are susceptible to diet-induced obesity. The results indicated that in FVB mice, high fat diet impairs skeletal acquisition at a young age, but has little effect on bone mass, architecture, or marrow adiposity in older animals. In B6 mice, high fat diet leads to overconsumption of food, increased body mass and fat mass, decreased trabecular number and connectivity density in the distal femur at 12 and 20 wks of age, and increased marrow adiposity at 12 wks of age. These results suggest that both high fat diet and diet-induced metabolic disease cause subtle alterations in bone mass and microarchitecture, although these effects are complex and vary in an age- and strain-dependent manner. Trabecular bone appears to be more sensitive to dietary and metabolic perturbations than cortical bone, perhaps due to its faster turnover. Protection of bone mass is an additional rationale for treating metabolic dysregulation, particularly during peak bone mass acquisition in adolescents.
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[^1]: Bolded values indicate significant pairwise differences within each strain at a given age (p \< 0.05). Pairwise comparisons were performed for variables with overall significance in the GLM, as shown at right.

[^2]: Bolded values indicate significant pairwise differences within each strain at a given age (p \< 0.05). Pairwise comparisons were performed for variables with overall significance in the GLM, as shown at right. Cortical bone variables that were significantly lower in HF vs. N mice (p \< 0.05) after body mass adjustment are indicated by ^\#^.

[^3]: Bolded values indicate significant pairwise differences within each strain at a given age (p \< 0.05). Pairwise comparisons were performed for variables with overall significance in the GLM, as shown at right.

[^4]: Bolded values indicate significant pairwise differences within each strain at a given age (p \< 0.05). Pairwise comparisons were performed for variables with overall significance in the GLM, as shown at right.
